Team

Our Team

HLS Therapeutics is led by a team of seasoned executives. Prior to founding HLS, our proven management team led the turnaround of Biovail Pharmaceuticals through its restructuring and ultimate merger with Valeant International.

EXECUTIVE TEAM

Executive Chairman of the Board – Bill Wells, BA, MBA

Co-Founder of HLS, Former Chief Executive Officer of Biovail Corporation Canada’s largest publicly traded pharmaceutical company.

Mr. Wells is a seasoned business executive with extensive experience managing complex global businesses. He has been involved in three successful turnaround efforts of major public companies and led the turnaround of Biovail, first as Lead Director of the board and then as CEO.

Chief Executive Officer – Greg Gubitz, BA, LLB

Co-Founder of HLS, Former Senior Vice President, Corporate Development and General Counsel of Biovail Corporation.

Mr. Gubitz is a seasoned executive and business lawyer, with significant transaction, investment & operating experience. As General Counsel of Biovail, he was responsible for mergers & acquisitions and for worldwide legal operations.

President and Chief Operating Officer – Gilbert Godin, BEng, MBA

Co-Founder of HLS, Former Executive VP and COO of Biovail Corporation.

More recently, Mr. Godin, built the team that successfully took the first Duchesnay approved product to market. He has held executive leadership positions in Canada, Europe and in the U.S., for MDS, Schering-Plough, and L’Oreal.

Director, Corporate Development – Joe MacLean, BCom, LLB

Co-Founder of HLS, also serves as CEO of AOI Capital, LLC, a private investment firm.

Mr. MacLean is a seasoned business executive with extensive experience in acquisitions, trading, origination, structuring and pricing experience in credit, equities, structured finance derivatives, life insurance and annuities. He is an early founding investor of Concordia Healthcare Corp.

Chief Scientific Officer – Chris Fibiger, PhD

Dr. Fibiger has authored or co-authored over 400 scientific papers and has served on a number of national and international scientific advisory boards, including National Institutes of Mental Health and the Medical Research Council of Canada.

Dr. Fibiger is a former Senior Vice President and CSO at Biovail Corporation. A highly experienced and recognized scientist, Dr. Fibiger has significant experience across a broad range of world leading companies. Previous positions include Global Head of Neuroscience at Amgen, the world’s largest biotechnology company, Vice President of Neuroscience Discovery Research at Eli Lilly and Professor and Head of the Division of Neuroscience at University of British Columbia.

VP Scientific Affairs – Jason A. Gross, PharmD

Dr. Gross spent five years at the National Institutes of Health (NIH) and the Food & Drug Administration (FDA).

Dr. Gross is a pharmaceutical executive with more than 20 years of experience focused on clinical development, regulatory affairs, manufacturing and quality assurance. He is a former VP of Scientific and Medical Affairs at Cipher Pharmaceutics, MDS Capital, and Zenith Goldline.

VP Legal & Intellectual Property – Rochelle K. Seide, PhD, JD

Former Vice President, Intellectual Property at Biovail Corporation.

Dr. Seide is a highly experienced senior life sciences lawyer and business executive who specializes in intellectual property matters. She has significant business development, transaction, portfolio management, and litigation experience, including managing Biovail’s IP related litigations in the US and Canada (including settlement negotiations).

VP Finance & Administration – Tim Hendrickson, MBA

Former executive with Cubist Pharmaceuticals through its acquisition by Merck & Co  in early 2015.

Mr. Hendrickson is a financial executive with over 15 years of experience at companies such as Procter & Gamble, P&G Pharmaceuticals and Warner Chilcott. He has held leadership roles in finance & accounting, forecasting & financial analysis, business development & planning, customer service, distribution and operations.

VP Commercial Operations – Sanjiv Sharma, MBA

Former SVP Worldwide Commercial & Country Head-US for NicOx, and VP Commercial for Duchesnay USA.

Mr. Sharma has been a pharmaceutical executive for over 25 years. He is equally experienced in large, mid-size and startups in North America and Asia, with national and global responsibility for General Management, Sales & Marketing, Market Access & Business Development. Mr. Sharma oversaw strategic marketing & planning for Biovail and spent 15 years with Sanofi-Aventis in Sales and Marketing leadership roles in Canada and the U.S.

VP Integration Management – Carmel Daughtery, PMP

Former Vice President, Project Management Office at Biovail Corporation.

Mrs. Daughtery is a multi-disciplinary life science executive with 25 years of experience focused in the pharmaceutical and medical device industry. She has a diverse background encompassing alliance management, project management, technical operations and product and process development, gained in small and Fortune Global 500 companies.

BOARD OF DIRECTORS

Executive Chairman of the Board – Bill Wells, BA, MBA

Co-Founder of HLS, Former Chief Executive Officer of Biovail Corporation, Canada’s largest publicly traded pharmaceutical company.

Mr Wells is a seasoned business executive with extensive experience managing complex global businesses. He has been involved in three successful turnaround efforts of major public companies and led the turnaround of Biovail, first as Lead Director of the board and then as CEO.

Chief Executive Officer – Greg Gubitz, BA, LLB

Co-Founder of HLS, Former Senior Vice President, Corporate Development and General Counsel of Biovail Corporation.

Mr. Gubitz is a seasoned executive and business lawyer, with significant transaction, investment & operating experience. As General Counsel of Biovail, he was responsible for mergers & acquisitions and for worldwide legal operations.

President and Chief Operating Officer – Gilbert Godin, BEng, MBA

Co-Founder of HLS, Former Executive VP and COO of Biovail Corporation.

More recently, Mr. Godin, built the team that successfully took the first Duchesnay approved product to market. He has held executive leadership positions in Canada, Europe and in the U.S., for MDS, Schering-Plough, and L’Oreal.

Director, Corporate Development – Joe MacLean, BCom, LLB

Co-Founder of HLS, also serves as CEO of AOI Capital, LLC, a private investment firm.

Mr. MacLean is a seasoned business executive with extensive experience in acquisitions, trading, origination, structuring and pricing experience in credit, equities, structured finance derivatives, life insurance and annuities. He is an early founding investor of Concordia Healthcare Corp.

Director, Independent – J. Spencer Lanthier

Former chief executive officer of KPMG Canada, is a member of the Order of Canada and has served on various boards including TMX Group and The Bank of Canada.

Mr. Lanthier served as Lead Director of Valeant Pharmaceuticals International, Inc., has been Director of Biovail Corporation and was Corporate Director of Ontario Genomics Institute. He has been recognized in the Financial Post’s Top 200 Chief Executive Officer listings. Mr. Lanthier was educated at McGill University and holds an Honorary Doctor of Law Degree from the University of Toronto.

Director, Independent – Yvon Bastien

Former chief executive officer of Sanofi Canada and currently serves on the boards of Helix BioPharma and Telesta Therapeutics.

Mr. Bastien has more than 25 years of very successful experience in the pharmaceutical industry, where he occupied senior positions both at the national and international levels. He has held executive positions at Laboratoire Debat in Paris, IMS Canada in Montreal, and Eli Lilly in Montreal.

Brand names you know. Safe and effective results you trust.